Boehringer Ingelheim and Zealand Pharma's Nash candidate fast tracked by FDA

Biotech group Zealand Pharma and German partner Boehringer Ingelheim have been given fast track designation by the US FDA for drug candidate BI 456906 meant to treat nonalcoholic steatohepatitis (Nash), Zealand Pharma reveals Wednesday.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Danish biotechnology firm Zealand Pharma and its German partner, Boehringer Ingelheim, can look forward to expedited case processing time of their drug candidate BI 456906 from the US Food and Drug Administration (FDA) now that the treatment has received fast-track status, informs Zealand Pharma in a statement Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading